UNSPSC 51111757: Teloxantrone

This classification denotes an anthrapyrazole antibiotic with the molecular formula C21H25N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 96521WL61B, chemically known as anthra(1,9-cd)pyrazol-6(2h)-one, 7,10-dihydroxy-2-(2-((2-hydroxyethyl)amino)ethyl)-5-((2-(methylamino)ethyl)amino)- but generally known as teloxantrone, which bears US NIH Compound Identifier 5364123. European Medicines Agency schedules Teloxantrone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10875MIG.

UNSPSC 51111757 Teloxone, a Commodity code, shows minimal alignment between its nominal scope and actual state and local procurement activity. The recent opportunities tagged under this code primarily reflect purchases of naloxone (a life-safety medication for opioid overdose reversal), generic multi-source pharmaceuticals distributed through cooperative purchasing, and medical and first aid supplies for emergency response — none of which are teloxantrone, a chemotherapy agent. State and local governments are buying pharmaceutical products and emergency medical consumables through a mix of issuing bodies: county health departments (Seminole County, Florida), state health commissions (Texas Health and Human Services Commission), municipal fire departments (City of Tampa), and regional cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance). The work spans procurement of finished pharmaceutical products for distribution to healthcare and emergency-response facilities, ranging from small targeted purchases to statewide multi-vendor cooperative contracts.

Recent activity clusters in the Southeast and upper Midwest, with specific opportunities posted by Seminole County, Florida (IFB for naloxone and drug deactivation systems, due July 26, 2023), the City of Tampa (IFB for medical and first aid supplies for the Fire Department Rescue Division, due March 13, 2026, estimated at $700,000), the Texas Health and Human Services Commission (RFI on direct-to-manufacturer pharmacy programs, April 3, 2026), and the Minnesota Multistate Cooperative Purchasing Alliance (RFP for generic pharmaceuticals and OTC products, due March 26, 2026, covering Minnesota and Oregon). The code appears to be misapplied in current sourcing systems; teloxantrone-specific procurement activity is not evident in these records.